Free tool
FAERS Monitor: Depo-Provera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020246 or its brand name (Depo-Provera, Medroxyprogesterone Acetate). Reports on generic versions are filed under their own applications.
Reports
32,474
Serious
27,392
84% of reports
Hospitalization
3,238
Death reported
486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- meningioma12,292
- breast cancer female3,020
- breast cancer1,857
- drug ineffective922
- headache780
- nausea777
- pain699
- weight increased697
- depression652
- unintended pregnancy647
- meningioma benign637
- off label use607
- fatigue603
- dizziness558
- anxiety517
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,555 |
| 2005 | 1,470 |
| 2006 | 1,242 |
| 2007 | 463 |
| 2008 | 433 |
| 2009 | 850 |
| 2010 | 2,477 |
| 2011 | 1,191 |
| 2012 | 807 |
| 2013 | 495 |
| 2014 | 570 |
| 2015 | 756 |
| 2016 | 856 |
| 2017 | 505 |
| 2018 | 463 |
| 2019 | 711 |
| 2020 | 573 |
| 2021 | 463 |
| 2022 | 759 |
| 2023 | 742 |
| 2024 | 919 |
| 2025 | 2,674 |
| 2026 | 11,499 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,685 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| meningiomaSignal | 12,292 | 2383.1 | 2297.3 | 6,256,229 |
| meningioma benignSignal | 637 | 1412.2 | 1230.0 | 281,913 |
| breast cancer femaleSignal | 3,020 | 82.4 | 79.5 | 215,677 |
| unintended pregnancySignal | 647 | 42.7 | 39.4 | 24,680 |
| breast cancerSignal | 1,857 | 13.1 | 12.6 | 20,505 |
| weight increasedSignal | 697 | 2.0 | 1.9 | 360 |
| depression | 652 | 1.9 | 1.7 | 260 |
| anxiety | 517 | 1.2 | 1.1 | 14 |
| headache | 780 | 0.8 | 0.8 | 37 |
| pain | 699 | 0.7 | 0.7 | 67 |
| dizziness | 558 | 0.7 | 0.7 | 60 |
| nausea | 777 | 0.6 | 0.6 | 168 |
| fatigue | 603 | 0.5 | 0.5 | 310 |
| drug ineffective | 922 | 0.5 | 0.4 | 650 |
| off label use | 607 | 0.4 | 0.4 | 428 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.